{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:57:32Z","timestamp":1785495452344,"version":"3.56.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimerism analysis is used in hematopoietic stem cell transplantation (HSCT) to evaluate donor engraftment and assess underlying disease status. Practices vary greatly amongst Canadian transplant centres, and currently, there are no consensus guidelines for testing methodology, time points, cellular source and clinical interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To review the current chimerism practice patterns for Canadian transplant centres and review current literature<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>We surveyed members of Cell Therapy and Transplant Canada (CTTC) via a web based application regarding chimerism practices nationwide with approximately half of all transplant centres responding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of centres used similar chimerism laboratory methodologies, though we identified key areas of heterogeneity across transplant centres, namely in the time points for testing and the cellular lineages evaluated. Implications and management of mixed donor chimerism also varied between centres resulting in variability of interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Review of current chimerism testing literature highlighted the improving sensitivities of novel testing methods available as well as testing specific cellular lineages to evaluate ongoing donor hematopoiesis. Our survey emphasizes the importance of advocating for a national standard in chimerism testing, and subsequent management based on chimerism results, to better inform clinical practice and to aid in development of prospective research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frtra.2026.1879340","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:59:46Z","timestamp":1785491986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimerism practices across Canadian transplant centres: review of current standards and variations"],"prefix":"10.3389","volume":"5","author":[{"given":"Matthew","family":"Gravina","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Lepic","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Berg","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]},{"name":"Escarpment Cancer Research Institute, Hamilton Health Sciences\/McMaster University","place":["Hamilton, ON, Canada"]},{"name":"Centre for Discovery in Cancer Research, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyash","family":"Dalmia","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Grafodatskaya","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci T.","family":"Butcher","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University","place":["Hamilton, ON, Canada"]},{"name":"Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Alexander","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Radford","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University","place":["Hamilton, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11814","DOI":"10.3390\/ijms241411814","article-title":"Chimerism testing by next generation sequencing for detection of engraftment and early disease relapse in allogeneic hematopoietic cell transplantation and an overview of NGS chimerism studies","volume":"24","author":"Liacini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","article-title":"Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the international bone marrow transplant registry and the American society of blood and marrow transplantation","volume":"7","author":"Antin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood-2023-187458","article-title":"Analysis of the impact of whole blood and T-cell donor chimerism after allogeneic stem cell transplant","volume":"142","author":"Radford","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1182\/blood.V114.22.3317.3317","article-title":"Immunological intervention triggered by decreasing CD34+lineage-specific donor cell chimerism to prevent relapse of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (HSCT)","volume":"114","author":"Rosenow","year":"2009","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.leukres.2024.107504","article-title":"Donor lymphocyte infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+) donor chimerism (DC) monitoring","volume":"142","author":"Indran","year":"2024","journal-title":"Leuk Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41409-020-0822-8","article-title":"Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines","volume":"55","author":"Vives","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/labmed\/lmac132","article-title":"A primer on chimerism analysis: a straightforward, thorough review","volume":"54","author":"Morris","year":"2022","journal-title":"Lab Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/17843286.2020.1754635","article-title":"Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature","volume":"76","author":"Delie","year":"2021","journal-title":"Acta Clin Belg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jcma.2018.06.005","article-title":"Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia","volume":"81","author":"Chen","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.leu.2402762","article-title":"Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Paris-Robert Debr\u00e9 experience","volume":"17","author":"Acquaviva","year":"2003","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/genes11090993","article-title":"Short tandem repeats (STRs) as biomarkers for the quantitative follow-up of chimerism after stem cell transplantation: methodological considerations and clinical application","volume":"11","author":"Navarro-Bail\u00f3n","year":"2020","journal-title":"Genes (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.leu.2402761","article-title":"Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience","volume":"17","author":"Kreyenberg","year":"2003","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1525-1578(10)60638-1","article-title":"Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis","volume":"2","author":"Oliver","year":"2000","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1182\/blood.V99.12.4618","article-title":"Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction","volume":"99","author":"Alizadeh","year":"2002","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/bmt.2014.254","article-title":"Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia","volume":"50","author":"Jacque","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41409-018-0176-7","article-title":"Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation","volume":"53","author":"Sellmann","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100673","DOI":"10.1016\/j.blre.2020.100673","article-title":"Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature","volume":"44","author":"Haugaard","year":"2020","journal-title":"Blood Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American society for transplantation and cellular therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/sj.leu.2401603","article-title":"Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection","volume":"13","author":"Dubovsky","year":"1999","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"374.e1","DOI":"10.1016\/j.jtct.2022.04.009","article-title":"Post-Transplantation day +100 minimal residual disease detection rather than mixed chimerism predicts relapses after allogeneic stem cell transplantation for intermediate-risk acute myelogenous leukemia patients undergoing transplantation in complete remission","volume":"28","author":"Klyuchnikov","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1055497","DOI":"10.3389\/fimmu.2022.1055497","article-title":"Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease","volume":"13","author":"Chu","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"268.e1","DOI":"10.1016\/j.jtct.2022.12.022","article-title":"Competitive repopulation and allo-immunologic pressure determine chimerism kinetics after T cell-depleted allogeneic stem cell transplantation and donor lymphocyte infusion","volume":"29","author":"Koster","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"229.e1","DOI":"10.1016\/j.jtct.2023.11.010","article-title":"Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood.V65.2.368.368","article-title":"Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes","volume":"65","author":"First","year":"1985","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3346\/jkms.2006.21.1.46","article-title":"Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation","volume":"21","author":"Kim","year":"2006","journal-title":"J Korean Med Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"780.e1","DOI":"10.1016\/j.jtct.2021.05.020","article-title":"Donor-Host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pretransplantation variables and correlation with post-transplantation outcomes","volume":"27","author":"Llaurador","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/bjh.70061","article-title":"UK Recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): best practice consensus guidelines from the British society for blood and marrow transplant and cellular therapies (BSBMTCT), NHS England genomic laboratory hub (GLH) haematological malignancies working group, UK cancer genetics group (UKCGG) and the UK national external quality assessment service for leucocyte immunophenotyping (UK NEQAS LI)","volume":"207","author":"Clark","year":"2025","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.bbmt.2008.07.013","article-title":"Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornhauser","year":"2009","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"841608","DOI":"10.3389\/fonc.2022.841608","article-title":"Analysis of subset chimerism for MRD-detection and Pre-emptive treatment in AML","volume":"12","author":"Georgi","year":"2022","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"454.e1","DOI":"10.1016\/j.jtct.2023.03.025","article-title":"Peripheral blood CD34 donor chimerism has greater clinical utility than CD3 for detecting relapse after allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome","volume":"29","author":"Das","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/bmt.2013.207","article-title":"Early CD3+\/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT","volume":"49","author":"Ketterl","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41409-022-01615-8","article-title":"Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"57","author":"Lindahl","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/cells13110993","article-title":"Prospects and potential for chimerism analysis after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Miura","year":"2024","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3904\/kjim.2000.15.3.224","article-title":"Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies","volume":"15","author":"Park","year":"2000","journal-title":"Korean J Intern Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3324\/haematol.2015.129650","article-title":"Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation","volume":"100","author":"Kekre","year":"2015","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.bbmt.2010.06.005","article-title":"Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions","volume":"16","author":"Sairafi","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbmt.2017.07.007","article-title":"Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained","volume":"23","author":"Caldemeyer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41409-019-0695-x","article-title":"Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)","volume":"55","author":"Feliu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1359113","DOI":"10.3389\/fimmu.2024.1359113","article-title":"Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect","volume":"15","author":"Murdock","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bbmt.2013.02.015","article-title":"Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients","volume":"19","author":"Stikvoort","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbmt.2017.12.801","article-title":"Evaluation of chimerism dynamics after allogeneic hematopoietic stem cell transplantation in children with nonmalignant diseases","volume":"24","author":"Faraci","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbmt.2019.10.004","article-title":"Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic Anemia","volume":"26","author":"Kako","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1365-2141.2008.07533.x","article-title":"Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA","volume":"144","author":"Lawler","year":"2009","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","article-title":"Exploring physician specialist response rates to web-based surveys","volume":"15","author":"Cunningham","year":"2015","journal-title":"BMC Med Res Methodol"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1879340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:59:48Z","timestamp":1785491988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2026.1879340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":54,"alternative-id":["10.3389\/frtra.2026.1879340"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2026.1879340","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1879340"}}